Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravesical idarubicin--a phase-I study

W Schultze-Seemann1, K Mross, K Burk

  • 1Department of Urology, University Hospital Freiburg, Germany.

Urological Research
|January 1, 1994
PubMed
Summary

This study on idarubicin bladder cancer treatment found higher drug concentrations in tumors than surrounding tissues. Minimal systemic absorption suggests potential for localized therapy with manageable local toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days' follow-up.

Prostate cancer and prostatic diseases·2021
Same author

Axon guidance receptors: Endocytosis, trafficking and downstream signaling from endosomes.

Progress in neurobiology·2020
Same author

[Treatment mapping of lower urinary tract symptoms due to benign prostatic hyperplasia-an analysis of the Governing Body of German Prostate Centers].

Der Urologe. Ausg. A·2020
Same author

A clinical diagnostic algorithm for early onset cerebellar ataxia.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2019
Same author

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

European urology focus·2018
Same author

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.

CPT: pharmacometrics & systems pharmacology·2017

Area of Science:

  • Pharmacology
  • Oncology
  • Urology

Background:

  • Idarubicin is an anthracycline chemotherapy agent.
  • Transurethral resection of bladder cancer (TURBT) is a common procedure.
  • Optimizing intravesical chemotherapy delivery is crucial for bladder cancer treatment.

Purpose of the Study:

  • To conduct a pharmacokinetic and dose-finding study of intravesical idarubicin before TURBT.
  • To determine the correlation between idarubicin dose, concentration, and tissue uptake in bladder cancer patients.
  • To assess systemic absorption and toxicity of intravesical idarubicin.

Main Methods:

  • 33 patients with bladder cancer received intravesical idarubicin instillations at 11 different doses (5-30 mg) and concentrations (0.25-1.5 mg/ml) 1 hour prior to TURBT.
  • Idarubicin tissue concentration (tumor and mucosa) and serum levels were measured.
  • Local and systemic toxicity were monitored.

Main Results:

  • A clear correlation was observed between idarubicin dose/concentration and tissue levels.
  • Significantly higher idarubicin concentrations were found in tumor tissue compared to bladder mucosa.
  • Minimal absorption into muscle tissue and low serum levels were detected.
  • Systemic toxicity was not observed; however, local toxicity occurred in 50% of patients.
  • Cytotoxic concentrations in the mucosa were achieved at doses >15 mg and concentrations >0.5 mg/ml.

Conclusions:

  • Intravesical idarubicin demonstrates favorable pharmacokinetics for bladder cancer treatment, with high tumor tissue concentrations and low systemic absorption.
  • Dose and concentration adjustments can achieve cytotoxic levels within bladder tumor tissue while potentially minimizing systemic effects.
  • These findings support further investigation in a Phase II study for intravesical idarubicin therapy in bladder cancer.

Related Experiment Videos